
|Videos|April 1, 2020
Sponsored: The Evolving Role of Stem Cell Transplant in Older AML Patients
Experts discuss the phase III SIERRA trial, which recently demonstrated durable complete responses in patients with acute myeloid leukemia<br />
Advertisement
Case 1: Primary Induction Failure (PIF)
Case 2: Early Relapse with Remission <6 months
Disease State of AML
SIERRA Trial Design
Hematopoietic
Hillard M. Lazarus, MD, FACP - Case Western Reserve University
Rajneesh Nath, MD - Banner MD Anderson Cancer Center Clinic
Alexander E. Perl, MD, MS - Hospital of the University of Pennsylvania
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5








































